1. CSIR-CDRI’s COVID-19 drug candidate Umifenovir secures DCGI approval for phase III clinical trial (2020) Available at: https://www.csir.res.in/slider/csir-cdri%E2%80%99s-covid-19-drug-candidate-umifenovir-secures-dcgi-approval-phase-iii-clinical-trial (accessed 26 June, 2020).
2. (ox.ac.uk, 2020) Dexamethasone reduces death in hospitalised patients with severe respiratory complications of COVID-19. Available at: http://www.ox.ac.uk/news/2020-06-16-dexamethasone-reduces-death-hospitalised-patients-severe-respiratory-complications (accessed on 1st July 2020).
3. Government Measures_Taken_in_Response_to_COVID-19.pdf. Available at: https://www.thompsonhine.com/uploads/1345/doc/Country-by-Country_Guide. (accessed on 28 June, 2020).
4. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle;Lu;J. Med. Virol.,2020
5. RDIF and ChemRar announce the Russian Ministry ofHealth has included Avifavir in the list of nationally recommended drugs for the treatment of COVID-19. https://rdif.ru/Eng_fullNews/5224/ (accessed on 4th June 2020).